RDCSB148 3264 3949
DIGEST
The digest printed below was prepared by House Legislative Services. It constitutes no part
of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute
part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]
SB 148 Engrossed 2024 Regular Session Mizell
Present law provides certain requirements for implementation of step therapy or fail first
protocols used by any commercial health coverage plan.
Present law requires health coverage plans that restrict medications through step therapy or
fail first protocol to have a process for the prescribing practitioner to request to override the
restriction if certain criteria are met.
Proposed law retains present law.
Proposed law further authorizes a prescribing practitioner to request an override if the health
coverage plan's required prescription drug for postpartum depression under a step therapy
or fail first protocol is not indicated by the U.S. Food and Drug Administration for
postpartum depression on the prescription drug's approved labeling.
(Adds R.S. 22:1053(C)(6))
Summary of Amendments Adopted by Senate
Committee Amendments Proposed by Senate Committee on Health and Welfare to
the original bill
1. Deletes the prohibitions against health coverage plans and managed care
organizations using step therapy or first fail protocol for the treatment of
postpartum depression.
2. Deletes the requirement for health coverage plans and managed care
organizations to cover screening for postpartum depression or related mental
health disorders.
3. Deletes provisions regarding effectiveness.
4. Adds requirement that a prescribing practitioner can request an override for
postpartum depression if certain conditions are met.
Summary of Amendments Adopted by House
The Committee Amendments Proposed by House Committee on Insurance to the
engrossed bill:
1. Modify proposed law to authorize a prescribing practitioner to request an
override if the required prescription drug for postpartum depression under a step
therapy or fail first protocol is not indicated by the U.S. Food and Drug
Administration for postpartum depression on the prescription drug's approved
labeling.
Page 1 of 1